©2022 Stanford Medicine
Early Blood Pressure Management in Extremely Premature Infants
Not Recruiting
Trial ID: NCT00874393
Purpose
This trial tests the feasibility of enrolling 60 extremely preterm infants in a randomized,
double-blinded study of blood pressure management within 12 months. Eligible infants will
receive an infusion drug (dopamine or a dextrose placebo) and a syringe drug (hydrocortisone
or a normal saline placebo).
Enrolled infants will be randomized to receive one of the following drug pairs:
- dopamine and hydrocortisone
- dopamine and normal saline
- dextrose and hydrocortisone
- dextrose and normal saline.
In addition to the intervention above, the NRN is conducting a 6-month time-limited
prospective observational study of all infants born at an NRN center between 23 and 26 weeks
gestational age. All clinical decisions made for these babies will be at the discretion of
the attending neonatologist/infant care team according to standard practice at each
institution. Data on blood pressure management in the first 24 postnatal hours collected for
each infant.
Official Title
Early Blood Pressure Management in Extremely Preterm Infants Feasibility Pilot Study
Stanford Investigator(s)
Eligibility
Inclusion Criteria:
- Inborn infants
- 23 0/7 to 26 6/7 weeks estimated gestational age
- Umbilical arterial catheter in place at study entry
- <= 24 hours of age
Exclusion Criteria:
- Terminally ill infants
- Infants that have received (prior to enrollment): >20 ml/kg in fluid boluses,
indomethacin, or ibuprofen
- Infants with major congenital anomalies
Intervention(s):
drug: Hydrocortisone
drug: Infusion Placebo
drug: Syringe Placebo
drug: dopamine
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
M Bethany Ball
6507258342